Our observation that intratumoral CTLA-4 might facilitate ESCC progression and diminish patient survival has important implications for the immunobiology and immunotherapeutic treatment of ESCC tumors. This evidence concerns the gene CTLA4 and esophageal squamous cell carcinoma.